Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Invested Capital (2016 - 2025)

Vanda Pharmaceuticals' Invested Capital history spans 16 years, with the latest figure at $334.7 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 38.42% year-over-year to $334.7 million; the TTM value through Dec 2025 reached $334.7 million, down 38.42%, while the annual FY2025 figure was $334.7 million, 38.42% down from the prior year.
  • Invested Capital for Q4 2025 was $334.7 million at Vanda Pharmaceuticals, down from $486.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $544.9 million in Q4 2023 and bottomed at $334.7 million in Q4 2025.
  • The 5-year median for Invested Capital is $513.5 million (2022), against an average of $507.0 million.
  • The largest annual shift saw Invested Capital rose 12.31% in 2021 before it plummeted 38.42% in 2025.
  • A 5-year view of Invested Capital shows it stood at $504.9 million in 2021, then increased by 4.41% to $527.2 million in 2022, then grew by 3.36% to $544.9 million in 2023, then fell by 0.26% to $543.5 million in 2024, then tumbled by 38.42% to $334.7 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Invested Capital are $334.7 million (Q4 2025), $486.3 million (Q2 2025), and $511.4 million (Q1 2025).